Products - Eye conditions | Topic | NICE

Showing 10 products

Date | Sort by Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Eculizumab for treating refractory myasthenia gravis [ID1064]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Brolucizumab for treating wet age-related macular degeneration [ID1254]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Artificial iris insertion for acquired aniridia
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Abicipar pegol for treating wet age-related macular degeneration ID1533
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders [ID1319]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Artificial iris insertion for congenital aniridia
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Conjunctivitis: antimicrobial prescribing
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
Stye: antimicrobial prescribing
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
Blepharitis: antimicrobial prescribing
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC